Serafin Morales - Dissemin

Papers authored by Serafin Morales

This paper was not found in any repository, but could be made available legally by the author.

2015 Ian Krop, Stephen Johnston, Ingrid A. Mayer, Maura Dickler, Vinod Ganju, Andres Forero-Torres, Bohuslav Melichar, Serafin Morales

, Richard de Boer, Steven Gendreau, Mika Derynck, Mark Lackner, Jill Spoerke, Ru-Fang Yeh, Gallia Levy and 14 other authors

Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results

Upload

Distributing this paper is prohibited by the publisher

Miguel Martín, Milagros González-Rivera, Serafín Morales

, Juan de la Haba-Rodriguez

, Lucía González-Cortijo, Luis Manso, Joan Albanell, Antonio González-Martín, Sónia González, Angels Arcusa, Luis de la Cruz-Merino, Federico Rojo, María Vidal

, Patricia Galván

, Elena Aguirre and 10 other authors

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

Upload

This paper is made freely available by the publisher.

M. Martin, Miguel Martín, Sibylle Loibl, Gunter von Minckwitz, Serafín Morales

, Noelia Martinez, Angel Guerrero, Antonio Anton, Bahriye Aktas, Winfried Schoenegg, Montserrat Munoz, J. A. Garcia-Saenz, José Ángel Garcia-Saenz, Miguel Gil, Manuel Ramos and 6 other authors

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

Download from doi.org

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

S. Morales Murillo

, A. Velasco Sánchez

Adjuvant systemic treatment in early HER2 positive breast cancer,Tratamiento médico adyuvante en cáncer de marna HER2 positivo

Upload

Serafin Morales

, Ana Velasco, Jose Vidal, Anna Serrate, Joan Valls, Juan Carlos Samame, Rafael Gisbert, Desamparados Moral, Antonio Llombart, Antonieta Salud, Xavier Matias-Guiu

Expression of circulating tumor cells (CTC) and CK-19 mRNA (CK19) as prognostic factors in heavily pretreated metastatic breast cancer

Upload

Juan de la Haba-Rodriguez, Serafin Morales

, Angel Guerrero, Noelia Martinez, Antonio Martinez Peinado, Antonio Anton, Montserrat Munoz-Mateu, Jose Angel Garcia Saenz, Manuel Ramos Vazquez, Miguel J. Gil Gil, Mireia Margeli, Sonia Servitja, Begona Bermejo, Josefina Cruz Jurado, Josefina Cruz Jurado and 6 other authors

Bevacizumab plus Letrozol (LEA clinical trial phase III). Using hypertension for finding biomarkers of efficacy

Download from doi.org

Francisco Ayala, Pedro Sánchez Rovira, Manuel Ruiz Borrego, Margarita Rodriguez Moral, Margarita Feijoo, Noelia Martinez, Jesús Florián Gericó, Amalia Gomez, Valero Pedro Jimenez, Nerea Ancizar Lizarraga, Sonia Candamio, Maria Helena Lopez de Ceballos, Guillermo Lopez-Vivanco, Serafin Morales

, Juan Virizuela Echaburu

Clinical profile and prognosis of metastatic breast cancer (MBC) patients with long-lasting response to eribulin (E): Results of the EXTER study.

Download from doi.org

2014 M. Martin, S. Beslija, E. Carrasco, Z. Kahan, M. J. Escudero, I. Láng, C. H. Bartlett, B. Bermejo, M. Inbar, J. I. Chacón, D. C. Jinga, J. A. García-Sáenz, J. La De Haba, M. Koehler, S. Morales

and 5 other authors

Phase III Study of Palbociclib in Combination with Exemestane Vs. Capecitabine, in Hormonal Receptor (Hr) Positive/Her2 Negative Metastatic Breast Cancer (Mbc) Patients with Resistance to Non-Steroidal Aromatase Inhibitors (Nsai): Pearl Study (Geicam/2013-02_Cecog/Bc.1.3.006)

Upload

Serafin Morales

, Ariadna Gasol Cud"s, Antonia Salud, Elena Maria Aguirre Ortega, NoemÃƒÂ Tuset Der-Abrain

Duration of lapatinib (L)-based therapy in HER2+ metastatic breast cancer (MBC) in a single institution.

Upload

Ramon Salazar, Serafin Morales

, Marta Gil-Martín, Elena Aguirre, Ana Oaknin, Margarita Garcia, Sophie Callies, Enaksha R. Wickremsinhe, Karim A. Benhadji, Antonio Llombart

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors

Upload

E. Aguirre, S. Morales

, A. Llombart

Other malignancies I. breast cancer

Upload

2013 Hs Rugo, O. Tredan, J. Ro, Sm Morales

, A. Musolina, N. Afonso, M. Ferreira, Kh Park, J. Cortes, Ar Tan, Jl Blum, L. Eaton, D. Mauro, C. Gause, E. Im and 1 other authors

Abstract OT2-6-13: A randomized phase 2 study of the triplet combination of ridaforolimus (RIDA), dalotuzumab (DALO) and exemestane (EX) compared to the ridaforolimus, exemestane doublet in high proliferation, estrogen receptor positive (ER+) advanced breast cancer

Upload

J. Baselga, Sm Morales

, A. Awada, Jl Blum, Ar Tan, M. Ewertz, J. Cortes, B. Moy, Kj Ruddy, T. Haddad, Em Ciruelos, P. Vuylsteke, S. Ebbinghaus, E. Im, L. Eaton and 4 other authors

Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer

Upload

Ce Barrios, A. Lluch, M. Ruiz-Borrego, J. Bines, L. Torrecillas, E. Carrasco, Jgm Segalla, A. Ruiz, Ja Garcia-Saenz, R. Torres, J. De la Haba-Rodriguez, E. Garcia-Martinez, S. Morales

, H. Gomez, J. Salvador-Bofill and 2 other authors

Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer (EBC):

Upload

Manuel Ruiz-Borrego, Juan Antonio Virizuela, José Ángel Garcia Saenz, Javier Hornedo, Luis Manso, Isabel Calvo, Juan Lao, Antonio González-Martín, Margarita Feijoo, Jesús Florián Gericó, Serafin Morales

, Jose J. Illarramendi, Valero Pedro Jimenez, Valero Pedro Jimenez, Javier Sánchez-Jiménez and 8 other authors

EUFORIA study (Eribulin Use for the Treatment of Advanced Breast Cancer: Observational, Retrospective Analysis): Initial experience with eribulin in daily clinical practice in Spain.

Upload

Manuel Ramos Vazquez, Cesar Augusto Rodriguez, Andrés Redondo, Ismael Ghanem, Miguel J. Gil Gil, Isabel Garau Llinas, Ramon Perez-Carrion, Elisa Garcia-Garre, Cesar Augusto Rodriguez, Jose Ignacio Chacon, Jose Ignacio Chacon, Guillermo Lopez-Vivanco, Antonia Perello, Ruth Espinosa Aunion, Serafin Morales

and 8 other authors

Long-term responders to first-line bevacizumab-based therapy among patients (pts) with HER2-negative metastatic breast cancer (MBC): Retrospective results of an ambispective observational study.

Upload

This paper is available in a repository.

P. Sánchez Rovira, M. A. Seguí, A. Llombart, E. Aranda, A. Antón, A. Sánchez, M. Lomas, A. Jaén, M. Fernández, I. Porras, E. Dalmau, S. Morales

, J. de la Haba Rodríguez, J. Haba Rodríguez

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

Download from link.springer.com

Elena Aguirre, Teresa Taberner, Armando Luaña, Serafin Morales

, Antonio Llombart

Severe Thrombocytopenia Related to Long-Term Trastuzumab Exposure

Upload

Serafin Morales

Protein expression profiling in patients with large residual breast cancer (> 1 cm) following primary systemic chemotherapy

Upload

Caranana, M. Ramos, E. Damau, J. A. Garcia-Saenz, X. Gonzalez, L. Murillo, L. Calvo, S. Morales

, A. Gonzalez-Farre, L. A. Fernandez-Morales, E. Carrasco, M. I. Casas, MdM Angulo, M. C. Camara, A. I. Garcia and 2 other authors

A prospective, open label, non-comparative trial to determine the incidence of chemotherapy-induced nausea and vomiting associated with the docetaxel-cyclophosphamide regimen in early breast cancer patients. Results from the GEICAM 2009-02 study

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

Papers authored by Serafin Morales